Contralateral Neurodynamic Mobilisation Improves Hamstring Flexibility.

NCT07648732 | Completed

• 1 other identifier: ethics number 1516-280
• Study Type: interventional
• Target: 20
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this clinical trial is to investigate whether single limb neurodynamic mobilizations increase active knee extension (AKE) range of motion (ROM) of the contralateral limb. 20 healthy participants (10 females and 10 males, age; 20.8+1.7 years, height; 1.7+ 0.1m, weight; 76.7+ 15.4kg). AKE was measured pre- and post- intervention and control. The main question it aims to answer are: It is hypothesized that contralateral neurodynamic mobilization will significantly increase AKE ROM in asymptomatic individuals. Participants were allocated sequentially in an alternating order to study groups. This method aims to balance group sizes while simplifying the assignment. AKE was measured immediately before and after the allocated condition. One week later, at the same time of day, participants returned to complete the opposing condition following a standardized washout period to minimize carryover effects between conditions.

• Completed a neurodynamic mobilisation on the contralateral limb 6x30seconds, 10 second rest between sets.
• When acting as the control sat quietly for 4 minutes to match the duration of the intervention condition.

Conditions

Range of Motion; Neuromuscular Signs and Symptoms; Wounds and Injury

Keywords

Slider; Range of Motion; Cross-Education; Neuromuscular System

Outcome Measures

Primary Outcomes (1)

• Active Knee Extension Test

  Data will be recorded three times to then take a mean. Active knee extension test will be performed utilising a bubble inclinometer placed on the participants tibial tuberosity. Standardised hip flexion to 90 degrees as the active knee extension is performed.

  Baseline (Day 1) and Day 7.

Study Arms (2)

Neurodynamic Group

EXPERIMENTAL

The neurodynamic technique was adapted from Castellote-Caballero12. The active neurodynamic sliding technique required the participant to sit on the edge of the bed with their feet off the floor. Participants sat in a slumped position with their thoracic and cervical spine flexed, knees flexed and feet plantar flexed. They then extended their cervical spine, extended their knee and dorsiflexed their foot before returning to the starting position, counting as one repetition. This was performed on the right leg for six sets of 30 seconds with a 10 second rest between sets, using a metronome app (ONYX 3, Apple, California) set at 60bpm. Participants flexed and extended their leg on each metronome beat, completing 90 repetitions in total.

Other: Neurodynamic Hamstring Mobilisation

Control Group

PLACEBO COMPARATOR

Following an initial active knee extension test measurement, participants in the control condition were instructed to sit quietly for 4 minutes to match the duration of the intervention condition.

Other: Neurodynamic Hamstring Mobilisation

Interventions

Neurodynamic Hamstring Mobilisation OTHER

Sciatic Neurodynamic slider performed on the right leg.

Control Group; Neurodynamic Group

Eligibility Criteria

• Age: 18 Years - 30 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy University students
• Aged 18-30
• participating in regular physical activity
• No current lower back pain
• No current illness
• No current hamstring injuries.

You may not qualify if:

• Participants aged 31 or over
• Did not partake in regular physical activity or
• Experienced lower back pain
• Currently suffering from an illness
• Currently sustained a hamstring injuries

Sponsors & Collaborators

• University of Salford: lead

MeSH Terms

Conditions

Neuromuscular Manifestations; Wounds and Injuries

Condition Hierarchy (Ancestors)

Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Charlotte A Park, MSc

  University of Salford

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 8, 2026
• First Posted: June 15, 2026
• Study Start: December 1, 2016
• Primary Completion: April 1, 2017
• Study Completion: December 1, 2017
• Last Updated: June 15, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share